A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
← catalyst calendarNCT06129864 · readout in 1,337 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Single · Treatment
Enrollment
1,145estimated
Sites
306
Countries
Austria, Belgium, Brazil +20
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-12-14 | actual | When the study began enrolling |
| Primary completion | 2030-04-17 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-02-28 | estimated | The whole study's end, after follow-up |
| First posted | 2023-11-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Locally Advanced Head and Neck Squamous Cell Carcinoma
Intervention
- Drug: volrustomig — also filed as MEDI5752
Primary outcome
what the primary-completion date above is the date OFProgression-Free Survival (PFS) in participants with unresected LA-HNSCC with PD-L1 expressing tumors
measured Up to approximately 8 years
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed